- Home
- HDSN vs YMAB Comparison
HDSN vs YMAB Comparison
Compare HDSN & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HDSN
- YMAB
- Stock Information
- Founded
- HDSN 1991
- YMAB 2015
- Country
- HDSN United States
- YMAB United States
- Employees
- HDSN N/A
- YMAB N/A
- Industry
- HDSN Industrial Specialties
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- HDSN Consumer Discretionary
- YMAB Health Care
- Exchange
- HDSN Nasdaq
- YMAB Nasdaq
- Market Cap
- HDSN 266.4M
- YMAB 218.4M
- IPO Year
- HDSN 1994
- YMAB 2018
- Fundamental
- Price
- HDSN $5.47
- YMAB $4.69
- Analyst Decision
- HDSN Hold
- YMAB Buy
- Analyst Count
- HDSN 4
- YMAB 11
- Target Price
- HDSN $6.88
- YMAB $18.73
- AVG Volume (30 Days)
- HDSN 458.9K
- YMAB 318.1K
- Earning Date
- HDSN 04-30-2025
- YMAB 05-06-2025
- Dividend Yield
- HDSN N/A
- YMAB N/A
- EPS Growth
- HDSN N/A
- YMAB N/A
- EPS
- HDSN 0.52
- YMAB N/A
- Revenue
- HDSN $237,118,000.00
- YMAB $87,685,000.00
- Revenue This Year
- HDSN N/A
- YMAB N/A
- Revenue Next Year
- HDSN $10.35
- YMAB $21.10
- P/E Ratio
- HDSN $10.52
- YMAB N/A
- Revenue Growth
- HDSN N/A
- YMAB 3.38
- 52 Week Low
- HDSN $5.11
- YMAB $3.86
- 52 Week High
- HDSN $10.84
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- HDSN 41.75
- YMAB 47.75
- Support Level
- HDSN $5.33
- YMAB $4.46
- Resistance Level
- HDSN $5.88
- YMAB $5.44
- Average True Range (ATR)
- HDSN 0.30
- YMAB 0.45
- MACD
- HDSN -0.04
- YMAB 0.07
- Stochastic Oscillator
- HDSN 32.73
- YMAB 52.53
About HDSN Hudson Technologies Inc.
Hudson Technologies Inc is an American industrial products manufacturer. It develops products which are mainly used in commercial air conditioning, industrial processing, and refrigeration systems. The company products include refrigerant and industrial gases, refrigerant management services and RefrigerantSide services, which consist of system decontamination. These are performed at customer's site using its Zugibeast system, which is a fast and portable system and allows the R-Side services team to accelerate critical services while saving customers time, money and aggravation. The company also owns a web-based real-time monitoring service which is used in the facility's refrigeration systems and other energy systems.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.